Veeva is a pure-play cloud computing company whose entire platform is delivered as a service, enabling life sciences companies to modernize operations.
Veeva Systems provides mission-critical cloud software to the life sciences and healthcare industry, helping pharmaceutical companies manage clinical trials and regulatory submissions.
Veeva Systems provides cloud-based software purpose-built for the life sciences industry, with a dominant position in pharmaceutical CRM and clinical data management driving strong recurring revenue.
Veeva is a leading vertical SaaS technology company with deep domain expertise, offering applications purpose-built for the regulated life sciences industry.
Data updated Feb 15 · Source: Twelve Data
Veeva Systems has long been considered the dominant vertical SaaS platform for the life sciences industry, but the stock has been under severe pressure, declining 25% over the past year and 37% over two months. Trading at a P/E of 23.8 with $7.33 EPS, the valuation has compressed dramatically from its historical premiums. The company is well below its 50-day moving average of $217.34 and far from its 52-week high of $310.50, indicating significant negative momentum. Veeva's transition from Salesforce to its own Vault platform introduces execution risk but could eventually improve margins and reduce dependency. The bull case rests on the essential nature of its regulatory and clinical software for pharma companies, continued expansion into new modules, and the depressed valuation creating an attractive entry point. The bear case involves competition from Salesforce and other enterprise platforms, slower pharmaceutical IT spending, and the disruptive risk of the platform migration. Veeva's fundamentals remain solid, but the market has clearly lost confidence in the near-term growth trajectory.
Latest from Otrai
Every trader has a strategy that looks great in their head. Backtesting is how you find out whether it actually works. Here is how to test strategies properly, what metrics matter, and why most backtest results are too good to be true.
A risk-reward ratio compares how much you stand to lose on a trade to how much you stand to gain. It is arguably the most important number in your trading plan, because it determines whether your strategy can survive a normal losing streak.
Every month, a handful of economic data releases move the forex market more in five minutes than most sessions move in five days. Non-Farm Payrolls, CPI prints, and central bank rate decisions create violent spikes, whipsaws, and trend shifts that can make or break a trading account.
A CFD is a contract between you and your broker to exchange the difference in an asset's price from when you open the trade to when you close it. You never own the underlying asset. That single distinction shapes everything about how CFDs work, what they cost, and why regulators treat them differently from traditional investing.
Powered by Rexiew